(Q39456933)

12 September 2017

Assessment of hormone refractory prostate cancer (English)

1 reference

12 September 2017

1 reference

2

Fosså SD

1 reference

12 September 2017

Newling D

1

1 reference

12 September 2017

Andersson L

3

1 reference

12 September 2017

Abrahamsson PA

4

1 reference

12 September 2017

Aso Y

5

1 reference

12 September 2017

Eisenberger MA

6

1 reference

12 September 2017

Khoury S

7

1 reference

12 September 2017

Kozlowski JS

8

1 reference

12 September 2017

Kelly K

9

1 reference

12 September 2017

Scher H

10

1 reference

12 September 2017

Hartley-Asp B

11

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 April 1997

1 reference

12 September 2017

1 reference

12 September 2017

49

1 reference

12 September 2017

46-53

1 reference

12 September 2017

4A Suppl

1 reference

Clinical trials in relapsed prostate cancer: defining the target

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980323-9

7 January 2021

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980323-9

7 January 2021

How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980323-9

7 January 2021

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980323-9

7 January 2021

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980323-9

7 January 2021

Hormone refractory disease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980323-9

7 January 2021

Suramin, an active drug for prostate cancer: interim observations in a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980323-9

7 January 2021

Quality of life after palliative radiotherapy in patients with hormone-resistant prostate cancer: single institution experience

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980323-9

7 January 2021

10.1016/S0090-4295(99)80323-9

Identifiers

DOI

1 reference

12 September 2017

1 reference